Scholarlink

<p>Severe eosinophilic asthma remains a major therapeutic challenge despite advances in biologic therapies targeting type 2 inflammation. Depemokimab (Exdensur®), a novel ultra-long-acting anti-interleukin-5 (IL-5) monoclonal antibody, introduces a new treatment paradigm through sustained eosinophil suppression and twice-yearly administration. Engineered with enhanced IL-5 binding affinity and fragment crystallizable (Fc) modifications that prolong systemic persistence, depemokimab achieves durable pharmacodynamic activity and extended dosing intervals. Phase III SWIFT-1 and SWIFT-2 trials demonstrated significant reductions in annualized asthma exacerbations, with efficacy comparable to established anti-IL-5 agents and a favorable safety profile. However, benefits in lung function, symptom control, and quality of life have been less consistent, underscoring the complex relationship between eosinophilic inflammation and broader disease manifestations. The principal advantage of depemokimab lies in its potential to reduce treatment burden, improve adherence, and decrease healthcare utilization. As severe asthma management evolves, depemokimab represents a promising patient-centered option, although optimal patient selection and long-term outcomes require further investigation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Depemokimab: toward biannual biologic therapy for severe eosinophilic asthma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月8日

查看全文
  • Kostas A. Papavassiliou,
  • Vassiliki A. Gogou,
  • Athanasios G. Papavassiliou

摘要

Severe eosinophilic asthma remains a major therapeutic challenge despite advances in biologic therapies targeting type 2 inflammation. Depemokimab (Exdensur®), a novel ultra-long-acting anti-interleukin-5 (IL-5) monoclonal antibody, introduces a new treatment paradigm through sustained eosinophil suppression and twice-yearly administration. Engineered with enhanced IL-5 binding affinity and fragment crystallizable (Fc) modifications that prolong systemic persistence, depemokimab achieves durable pharmacodynamic activity and extended dosing intervals. Phase III SWIFT-1 and SWIFT-2 trials demonstrated significant reductions in annualized asthma exacerbations, with efficacy comparable to established anti-IL-5 agents and a favorable safety profile. However, benefits in lung function, symptom control, and quality of life have been less consistent, underscoring the complex relationship between eosinophilic inflammation and broader disease manifestations. The principal advantage of depemokimab lies in its potential to reduce treatment burden, improve adherence, and decrease healthcare utilization. As severe asthma management evolves, depemokimab represents a promising patient-centered option, although optimal patient selection and long-term outcomes require further investigation.